UBS Raises Kenvue Inc. (KVUE) Price Target to $19 After Strong Q4 Results

Core Viewpoint - UBS and Citigroup have raised their price targets for Kenvue Inc. following strong fourth-quarter results, indicating positive market sentiment towards the company's performance and growth potential [1][2]. Group 1: Price Target Adjustments - UBS increased Kenvue's price target to $19 from $17 while maintaining a Neutral rating after the company reported better-than-expected fourth-quarter results [1]. - Canaccord Genuity also raised its price target to $18 from $17, keeping a Hold rating, highlighting that Kenvue beat expectations on both revenue and earnings [1]. - Citigroup raised its price target to $20 from $18, also maintaining a Neutral rating, following Kenvue's reported revenue of $3.78 billion for Q4 2025, which exceeded the consensus estimate of $3.69 billion [2]. Group 2: Company Performance - Kenvue's fourth-quarter results showed year-over-year growth in all three business segments for the first time since Q2 2023, aided by favorable foreign exchange conditions [1]. - CEO Kirk Perry noted that the company ended 2025 with stronger performance due to disciplined execution of strategic priorities and easier year-over-year comparisons [2]. - Kenvue Inc. was founded in 2022 as a spin-off from Johnson & Johnson and operates as a major global consumer health firm with a portfolio that includes well-known brands like Tylenol, Neutrogena, Band-Aid, Listerine, and Aveeno [3].